Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Revance Therapeutics, Inc. RVNC
$34.47
-$1.21 (-3.50%)
На 18:00, 12 мая 2023
-4.26%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2977097658.00000000
-
week52high
37.98
-
week52low
11.27
-
Revenue
132565000
-
P/E TTM
-8
-
Beta
0.84013800
-
EPS
-5.17000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Barclays | Overweight | Overweight | 26 окт 2021 г. |
| Wells Fargo | Equal-Weight | Overweight | 25 окт 2021 г. |
| Needham | Buy | Buy | 18 окт 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 18 окт 2021 г. |
| Barclays | Overweight | Overweight | 06 авг 2021 г. |
| Needham | Buy | Buy | 09 сент 2022 г. |
| Mizuho | Buy | Buy | 09 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 09 сент 2022 г. |
| Barclays | Overweight | Overweight | 09 сент 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 25 авг 2022 г. |
| Goldman Sachs | Buy | 22 сент 2022 г. | |
| Morgan Stanley | Equal-Weight | 11 окт 2022 г. | |
| Barclays | Overweight | Overweight | 16 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 ноя 2022 г. |
| Needham | Buy | Buy | 10 янв 2023 г. |
| Piper Sandler | Overweight | Overweight | 31 янв 2023 г. |
| HC Wainwright & Co. | Buy | Buy | 26 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Schilke Tobin | D | 54676 | 3201 | 01 февр 2023 г. |
| Sjuts Dustin S | A | 43255 | 43255 | 31 янв 2023 г. |
| Moxie Dwight | A | 43774 | 43774 | 31 янв 2023 г. |
| Schilke Tobin | D | 50435 | 50435 | 31 янв 2023 г. |
| Schilke Tobin | D | 57877 | 1000 | 20 янв 2023 г. |
| Schilke Tobin | D | 58877 | 1000 | 09 янв 2023 г. |
| Schilke Tobin | D | 59877 | 1000 | 09 янв 2023 г. |
| Schilke Tobin | D | 60877 | 1701 | 09 янв 2023 г. |
| Foley Mark J | A | 718092 | 605 | 31 дек 2022 г. |
| Sjuts Dustin S | A | 95812 | 605 | 31 дек 2022 г. |
Новостная лента
This Botox Rival Has Investors Smiling With A 100% Gain This Year. The Stock Broke Out Today.
Investors Business Daily
09 мая 2023 г. в 14:16
Revance Therapeutics, a biotech stock, is at a 52-week high and reports earnings Tuesday. Their frown line treatment lasts longer than Botox.
Top 4 Stocks Set to Beat on Earnings Today After Market Closes
Zacks Investment Research
09 мая 2023 г. в 07:38
We have narrowed our search to four stocks that are set to report earnings results today after market closes. These are: WYNN, CELH, RVNC and IAC.
7 Stocks to Buy for the Massive Rally Ahead
InvestorPlace
04 апр 2023 г. в 23:15
Well-known investment advisor Ed Yardeni believes that U.S. stocks are poised to rally this year. Speaking to CNBC last week, Yardeni said that the banking mini-crisis will be “very well-contained” by the Federal Reserve and Federal Deposit Insurance Corporation (FDIC).
Revance Therapeutics: Rally Seems Due For A Pause
Seeking Alpha
03 апр 2023 г. в 19:57
Today, we take a deeper look at Revance Therapeutics, Inc., a developer of aesthetic products that is seeing rapid revenue growth. The company has potential catalysts on the horizon but is bumping up against analyst price targets and has a high cash burn rate.
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
MarketBeat
02 мар 2023 г. в 07:21
Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn't have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February.